CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms CASPALLO
- 25 Sep 2014 Planned End Date changed from 1 Apr 2026 to 1 Jul 2026 as reported by ClinicalTrials.gov record.
- 05 Feb 2014 Planned End Date changed from 1 Aug 2028 to 1 Apr 2026 as reported by ClinicalTrials.gov.
- 13 Apr 2012 Planned end date changed from 1 Aug 2013 to 1 Aug 2028 as reported by ClinicalTrials.gov.